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Melanocortin-1 Receptor Variant R151C Modifies Melanoma Risk
in Dutch Families with Melanoma
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Germline mutations of the cell-cycle regulator p16 (also called “CDKN2A”) in kindreds with melanoma implicate
this gene in susceptibility to malignant melanoma. Most families with familial atypical multiple-mole melanoma
(FAMMM) who are registered at the Leiden dermatology clinic share the same p16-inactivating deletion (p16-
Leiden). Incomplete penetrance and variable clinical expression suggest risk modification by other genetic and/or
environmental factors. Variants of the melanocortin-1 receptor (MC1R) gene have been shown to be associated
with red hair, fair skin, and melanoma in humans. Carriers of the p16-Leiden deletion in Dutch families with
FAMMM show an increased risk of melanoma when they also carry MC1R variant alleles. The R151C variant is
overrepresented in patients with melanoma who are from families with the p16-Leiden mutation. Although some
of the effect of the R151C variant on melanoma risk may be attributable to its effect on skin type, our analyses
indicate that the R151C variant contributes an increased melanoma risk even after statistical correction for its
effect on skin type. These findings suggest that the R151C variant may be involved in melanoma tumorigenesis in
a dual manner, both as a determinant of fair skin and as a component in an independent additional pathway.
Introduction
Cancer is a complex multifactorial process in which gene-
gene and gene-environment interactions are thought to
play crucial roles. Identification of genes involved in mel-
anoma skin cancer has been difficult, except in cases of
very strong familial risk (Hussussian et al. 1994; Kamb
et al. 1994b; Zuo et al. 1996). A candidate melanoma-
susceptibility gene, p16 (also called “CDKN2A” [MIM
600160]), has been isolated from the 9p21 region (Kamb
et al. 1994a; Nobori et al. 1994). Strong evidence for its
candidacy as a melanoma-predisposition gene has been
provided by germline mutations in ∼40% of all kindreds
with melanoma (Piepkorn 2000). p16 is a cell-cycle reg-
ulator, which fulfils its function by binding to cyclin-de-
pendent kinases 4 (CDK4 [MIM 123829]) and 6 (CDK6
[MIM 603368]) (Serrano et al. 1993). In this way, p16
inhibits the kinase activity of CDK4/cyclinD and CDK6/
cyclinD, which normally phosphorylate the retinoblas-
toma protein (pRB). Phosphorylation of pRB leads to
progression of the cell into the S phase of the cell cycle
(Serrano et al. 1993).
Fair skin is an additional known risk factor for mel-
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anoma (Kricker et al. 1991; Bliss et al. 1995). Variation
in human skin pigmentation is due to varied amounts
of eumelanin (brown/black) and pheomelanin (red) pro-
duced by melanocytes. The melanocortin-1 receptor
(MC1R [MIM 155555]) is a regulator of eumelanin and
pheomelanin production after binding of the melano-
tropic hormone, a-melanocyte–stimulating hormone
(aMSH). In humans, variants of the MC1R gene are of
key significance in determining the pigmentary pheno-
type and response to ultraviolet radiation (Valverde et
al. 1995; Box et al. 1997; Smith et al. 1998; Healy et
al. 2000; Palmer et al. 2000). The MC1R variants
R151C, R160W, and D294H have been particularly as-
sociated with fair skin and with skin cancer (Valverde
et al. 1995; Smith et al. 1998; Flanagan et al. 2000;
Healy et al. 2000; Palmer et al. 2000). In these studies,
one variant in the genotype turned out to be sufficient
to cause fair skin and increased melanoma risk (Healy
et al. 2000; Palmer et al. 2000). Several studies have
shown that specific MC1R gene variants act as inde-
pendent genetic risk factors for skin cancer in general
and that these MC1R variants contribute to skin cancer
risk at least as strongly as do fair skin and red hair
(Palmer et al. 2000).
In six Dutch families with familial atypical multiple-
mole melanoma (FAMMM), a 19-bp germline deletion
(p16-Leiden) in exon 2 of the p16 gene has been found
to be present (Gruis et al. 1995b). Incomplete pene-
trance and variable clinical expression suggest riskmod-
ification by other genetic and/or environmental factors
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in these kindreds (Gruis et al. 1995a; Hayward 1996).
In the present study, we determined the role of MC1R
variants as modifiers of melanoma risk in members of
Dutch families with FAMMM who are known to carry
p16-Leiden. In these families, variant alleles increase the
risk of melanoma. In particular, the fair-skin MC1R
variant R151C was found to be associated with mela-
noma risk in p16-Leiden carriers. Although it appears
that some of the increased risk in R151C-positive p16-
Leiden carriers can be attributed to the fair skin type
that is associated with this variant, our stratified statis-
tical analysis supports the notion that R151C also con-
tributes an increased risk that is independent of its effect
on skin type. This is consistent with the fact that MC1R
is a member of the G-protein–coupled receptor super-
family, the members of which can act as oncogenes in
other signal-transducing systems, including the p38 mi-
togen-activated protein (MAP) kinase pathway (Cough-
lin 1994; Simonds 1999; Smalley and Eisen 2000).
Material and Methods
Family Material and Control Subjects
All of the pedigree data, the method of ascertainment,
and the histopathological findings on the six 9p-linked
Dutch families with FAMMM syndrome have been pub-
lished elsewhere (Bergman et al. 1992). From these fam-
ilies, 101 carriers of p16-Leiden were included in the
single-strand conformation polymorphism (SSCP; Orita
et al. 1989) analysis of MC1R.
Skin type was assessed by the skin-type classification
of Fitzpatrick and Breathnach (1963). In this classifi-
cation, “Caucasian” (white) skin is divided into three
skin phenotypes (Fitzpatrick and Breathnach 1963): skin
type I represents fair skin that always burns and never
tans but frequently freckles in the sun; skin type I is
accompanied by red hair. Skin type II is lightly pig-
mented, easily burned, and yields a light sun tan; most
individuals with skin type II have fair hair and blue eyes.
Skin type III is still a white skin type, characterized by
easy tanning and infrequent burning in the sun. These
individuals tend to have brown hair and brown eyes.
Skin type IV never burns, always tans with ease, and is
not regarded as a white skin type.
Detection of MC1R Variants
Genomic DNA from members of the Dutch families
with FAMMM was isolated from peripheral blood leu-
kocytes by routine methods (Miller et al. 1988). A spe-
cific PCR product of MC1R coding sequence (GenBank
accession number X65634) was digested by 2 U of either
RsaI or MspI and was screened for mutations by SSCP
analysis (Orita et al. 1989) on a 6% polyacrylamide gel
with 10% glycerol. The gels were run at room temper-
ature for 6 h at 26 W or for 16 h at 20 W, for MspI
and RsaI digests, respectively. PCR reaction mixtures
contained 60 mM Tris HCl, pH 10.0; 2.0 mM MgCl2;
15 mM (NH4)2SO4; 100 mM dGTP, dTTP, dATP, and
dCTP; 1 ml a-[32P]dCTP (3,000 Ci mmol1), 500 ng of
each PCR primer, 2 U AmpliTaq (Perkin Elmer Cetus);
and 10% dimethyl sulfoxide, in a total volume of 100
ml. Fifty nanograms of genomic template DNA was
added to 10 ml of reaction mixture. Samples were cov-
ered with mineral oil, were denatured for 4 min at 92C,
and were passed through 33 cycles of amplification,
which consisted of 50 s of denaturation at 92C, 50 s
of primer annealing at 60C, and 2 min of elongation
at 72C. The amplifications were performed in 0.5 ml
tubes (Perkin Elmer). The DNA sequences of the primers
were as follows: forward, 5′-CAACGACT-CCTTCC-
TGCTTC-3′ and reverse, 5′-TGCCCAGCACACTTAA-
AGC-3′, resulting in a 1,018-bp PCR fragment.
Sequence Analysis
For sequence analysis, internal primers were used to
amplify MC1R in two fragments, which were purified by
the EasyPrep PCR Product Prep Kit (Pharmacia Biotech).
Products were directly sequenced by the AmpliCycle Se-
quencing Kit (Perkin Elmer) with the amplification prim-
ers. The sequences of the internal primers were as follows:
forward, 5′-ACCTGCAGCTCCAT-GCTGTC-3′ and re-
verse, 5′-GTCACGATGCTGTGGTAGC-3′.
Statistical Analysis
For comparison of the allele frequencies in different
groups, either Pearson’s x2 test or Fisher’s exact test was
applied, depending upon which test was more appro-
priate. The effect that the number of MC1R variants in
the genotype had on melanoma risk was evaluated using
logistic regression. TheMantel-Haenszel x2 test was used
to test the effect of the MC1R variant R151C on mel-
anoma risk, conditional on skin type.
Results
We studied the role of MC1R variants in six Dutch fam-
ilies with FAMMM, in whom p16-Leiden is segregating
(Gruis et al. 1995a). Mutation analysis of the entire
MC1R coding sequence was performed in 101 p16-Lei-
den carriers from these families, of whom 38 had de-
veloped a melanoma. Allele frequencies for six MC1R
variants detected in p16-Leiden carriers are presented in
table 1, together with the frequency data from a large
Dutch control population. In general, frequencies of var-
iants in the p16-Leiden carriers paralleled those in the
control population; exceptions included the R151C var-
iant, which was present in ∼14% of the family members,
in contrast with a general population frequency of 5%
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Table 1
Allele Frequencies of MC1R Variants in 101 Typed p16-Leiden Carriers
SAMPLE
FREQUENCY (NO.) OF MC1R VARIANT
V60L V92M R151C I155T R160W R163Q
All p16-Leiden carriers ( )np 101 .074 (15) .089 (18) .139 (28) .035 (7) .149 (30) .069 (14)
p16-Leiden carriers without melanoma ( )np 63 .071 (9) .095 (12) .095 (12) .016 (2) .127 (16) .087 (11)
p16-Leiden carriers with melanoma ( )np 38 .079 (6) .079 (6) .211 (16) .066 (5) .182 (14) .039 (3)
General population ( )anp 385 .083 (64) .069 (53) .048 (37) .003 (3) .105 (81) .049 (38)
a Allele frequencies estimated in 385 control individuals from The Netherlands (Bastiaens et al. 2001).
Table 2
Association between MC1R Variants and Melanoma Risk in 101
p16-Leiden Carriers
MC1R
Genotype
No. of
Carriers
No. of Melanoma
Cases (Frequency)
Age at Onset
(years)
Wt/Wt 17 3 (.18) 40
Wt/Var 55 19 (.35) 34
Var/Var 29 16 (.55) 42
Wt/R151C 10 5 (.50) 42
Var/R151C 17 11 (.65) 45
NOTE.—Wt p wild type; Var p variant.
( ), and the I155T variant ( ). The excess6P ! 10 P ≈ .001
of the R151C allele in the p16-Leiden carriers is mostly
due to a high frequency in the melanoma patients (21%;
table 1). Carriers without melanoma also present a
higher frequency of the R151C allele than does the gen-
eral population (10% vs. 5%); this indicates that these
melanoma pedigrees are enriched for this allele. A plau-
sible reason for this enrichment can be found in the
ascertainment procedure: only families with many mel-
anoma patients were collected in the very early stages
of our study. If the R151C allele indeed increases mel-
anoma risk, as our results indicate, the frequency of this
allele should be increased in these families, as a conse-
quence of the ascertainment procedure. Therefore, we
have determined the transmission distortion of the
R151C allele, and not merely the allele frequency, in the
families included in our study. Within the families, the
R151C allele was transmitted from heterozygous parents
carrying p16-Leiden to affected offspring more often
than expected by chance. Of 12 p16-Leiden–positive off-
spring with melanoma, 8 had received the R151C allele
from their heterozygous parents; however, of 16 unaf-
fected offspring (all carrying p16-Leiden), only 6 had
inherited the R151C allele ( , one sided).P ≈ .07
When all MC1R variant alleles were considered
jointly as a potential melanoma risk factor in p16-Lei-
den carriers, a similar pattern was observed. Overall,
38% of the p16-Leiden carriers developed melanoma.
Table 2 shows a melanoma frequency of 55% in p16-
Leiden carriers with two MC1R variants, compared to
a melanoma frequency of 18% inMC1Rwild-type p16-
Leiden carriers. Logistic regression showed that themel-
anoma risk increases with the number of MC1R vari-
ants in the genotype ( ), with an odds ratio (OR)P ≈ .01
of 2.4 for each additional MC1R variant in the geno-
type. When this analysis was performed with subjects
who had R151C alleles excluded, the OR per MC1R
variant was still increased (OR 1.8), but it did not differ
significantly from 1.0 ( ). The age at onset forP ≈ .16
melanoma was very similar in all genotype groups, vary-
ing between 34 years in the group with one MC1R
variant and 42 years in the group with two MC1R
variants. No significant differences were found between
the genotype groups for the current age distribution in
unaffected individuals. The distribution of skin types in
p16-Leiden carriers was determined and found not to
differ significantly from the control population (table
3); however, within the group of p16-Leiden carriers, a
significant difference in the skin type distribution existed
between subjects with and without melanoma (P ≈
), with a preponderance of fair skin types among.02
melanoma patients. Subsequently, the effect of the
MC1R variant R151C on melanoma risk was evaluated
with a correction for the existing relationship between
R151C and fair skin and for the increased melanoma
risk in people with fair skin. A Mantel-Haenszel test
conditional on skin type yielded a x2 of 2.78 ( ,P ≈ .05
one sided), which supports, albeit with marginal sig-
nificance, that the R151C variant independently con-
tributes to melanoma risk.
Discussion
The incidence of cutaneous melanoma in white individ-
uals has doubled roughly every 10 years since the early
part of last century (Henderson et al. 1991). Much of
this increase has been attributed to excessive sun ex-
posure. Despite this major environmental risk factor, it
is clear that individuals are variably susceptible to mel-
anoma development. For example, melanoma is essen-
tially a tumor of white-skinned people (Armstrong and
Kricker 1996), and, within this population, individuals
with skin that burns easily in the sun (skin types I and
II), seem to be at significantly increased risk (Osterlind
et al. 1988). Melanin pigment protects the skin from the
damaging effects of ultraviolet radiation. Whereas 150
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Table 3
Skin-Type Distribution of the Dutch General Population and of p16-Leiden Carriers
SAMPLE
NO. OF INDIVIDUALS WITH (FREQUENCY OF) SKIN TYPE
I II III IV
All p16-Leiden carriers ( )anp 90 10 (.11) 38 (.42) 42 (.47) …
p16-Leiden carriers without melanoma ( )np 58 3 (.05) 23 (.40) 32 (.55) …
p16-Leiden carriers with melanoma ( )np 32 7 (.22) 15 (.47) 10 (.31) …
General population ( )bnp 385 25 (.07) 155 (.40) 181 (.47) 24 (.06)
a Skin-type data were avaliable for 90 of the 101 p16-Leiden carriers.
b Skin-type assessment is from the study by Bastiaens et al. (2001).
loci determine coat color in mice (Jackson et al. 1994;
Jackson 1997), variation in hair and skin color in hu-
mans has so far been associated with polymorphisms at
only 1 locus, MC1R (Valverde et al. 1995), although
others are clearly involved, as is shown by sib pairs iden-
tical by descent for both parental MC1R alleles having
quite different pigmentation (Box et al. 1997). In several
studies, mutation screening in the general population has
shown that MC1R variants are common among all skin
types, although some are significantly associated with
fair skin—for example, R151C, and, to a lesser extent,
R160W (Smith et al. 1998; Flanagan et al. 2000; Healy
et al. 2000; Palmer et al. 2000). Initial studies of the
relationship between MC1R gene variants and mela-
noma risk were not conclusive, possibly because of small
sample sizes (Valverde et al. 1996; Healy et al. 1999);
however, several more-recent studies (Healy et al. 2000;
Palmer et al. 2000; Box et al. 2001 [in this issue]; Ken-
nedy et al., in press) have shown a relationship between
the MC1R genotype and both familial and sporadic mel-
anoma risk. In an Australian population-based sample
consisting of 460 individuals with familial and sporadic
melanoma and 399 control individuals, a strong rela-
tionship was observed between MC1R variants and skin
type (Healy et al. 2000; Palmer et al. 2000). Further-
more,MC1R variants were present in 72%ofmelanoma
cases and in 56% of the control individuals. The variant
alleles R151C, R160W, and D294H resulted in doubled
melanoma risk for each additional allele carried; thiswas
also observed in the study by Box et al. (2001 [in this
issue]) on familial melanoma. In the study by Palmer et
al. (Healy et al. 2000; Palmer et al. 2000) the association
between melanoma andMC1R variants persisted among
individuals reporting a medium or olive/dark complex-
ion. Similar results were obtained in a study of 123 pa-
tients with sporadic melanoma and 385 controls in The
Netherlands (Kennedy et al., in press). Compound het-
erozygote and homozygote carriers of the V60L, V92M,
R142H, R151C, R160W, R163Q, and H260P alleles
had ORs of ∼4 to develop melanoma, whereas hetero-
zygotes for these variants had half the risk. Again, the
predisposition turned out to be largely independent of
skin type. The effect of MC1R variant alleles on both
sporadic melanoma and familial melanoma therefore
seems to be partly mediated via determination of pig-
mentation phenotype, and the MC1R alleles involved
seemingly negate the protection normally afforded by a
darker skin color. This is in agreement with the findings
presented here. Although the sample size in our study is
modest, the effects of various tentative melanoma risk
factors can be evaluated more easily, since they are mea-
sured in a sample of individuals who all carry the same
p16 mutation. We found an increased frequency of
MC1R variants—in particular, of variant R151C—in
patients with melanoma. Furthermore, we were able to
show that within families the R151C allele was trans-
mitted from heterozygous parents to 150% of mela-
noma-positive offspring and to !50% of melanoma-free
offspring. This transmission distortion indicates that the
increased frequency of R151C in melanoma patients is
not simply a consequence of the relatively close family
relationships that exist between some of the individuals
in our sample. Although it appears that some of the
increased risk in R151C-positive p16-Leiden carriers can
be attributed to the fair skin type that is associated with
this variant, our stratified statistical analysis supports
the notion that R151C also contributes an increased risk
that is independent of its effect on skin type.
The best-described signal transduction pathway for
the G-protein–coupled receptor MC1R results in ele-
vated levels of intracellular cAMP, which lead to an
increased expression of tyrosinase and a switch from
the synthesis of pheomelanin to that of eumelanin (Rob-
bins et al. 1993). MC1R regulates the cAMP levels in
the cell, via adenylate cyclase. The R151C amino acid
change is present in the second cytoplasmatic loop of
the receptor. Limited functional studies have suggested
that R151C creates a change in MC1R function, af-
fecting cAMP signaling (Frandberg et al. 1998; Rees et
al. 1999; Schioth et al. 1999). When expressed in het-
erologous cells, the receptor bearing the R151C amino
acid change showed binding affinity to a-MSH com-
parable to that of wild-type MC1R, although the var-
iant was unable to stimulate cAMP production as
strongly as the wild-type receptor. For us to better un-
derstand the relevance of MC1R mutations in mela-
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noma risk, future studies will have to elucidate the func-
tional properties of the variants in the target cell itself,
the melanocyte. Although molecular details of MC1R
signaling are not fully understood, the preliminary new
insights in MC1R signal transduction (Coughlin 1994;
Simonds 1999; Smalley and Eisen 2000) assume that
the receptor is involved not only in pigment production
but also in additional signaling pathways which evoke
different biological responses.
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